BPMX BioPharmX Corporation. Common

0.64
+0.0089  (1%)
Previous Close 0.63
Open 0.63
Price To book 28.70
Market Cap 43.35M
Shares 67,719,000
Volume 1,403,559
Short Ratio 2.83
Av. Daily Volume 2,119,270

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 to be initiated in 2017
BPX-03
Moderate to severe periodic breast pain associated with FBC (fibrocystic breast condition) and cyclic mastalgia
Phase 2b data released May 3, 2017 - primary endpoint met, secondary missed.
BPX-01
Acne

Latest News

  1. ETFs with exposure to BioPharmX Corp. : May 23, 2017
  2. BioPharmX to Host "State of Acne" Symposium on June 1
  3. BioPharmX Reports Positive Topline Results of BPX-01 Topical Minocycline for Acne
  4. BioPharmX Announces Closing of $5.0 Million Offering
  5. BioPharmX Announces $5.0 Million Offering
  6. BioPharmX Corp. :BPMX-US: Earnings Analysis: Q4, 2017 By the Numbers : April 25, 2017
  7. BioPharmX Completes Last Subject Visit in its Phase 2b Trial of BPX-01, Expects to Report Topline Results First Half of May 2017
  8. BioPharmX AACR Poster Will Present Findings Suggesting Molecular Iodine Inhibits Breast Cancer Cell Growth and Drives Cancer Cell Death
  9. BioPharmX Reports Fourth Quarter and Full Year 2017 Financial Results
  10. BioPharmX Invited to Present at 27th Annual Oppenheimer Healthcare Conference
  11. BioPharmX to Report Fourth Quarter and Full Year Financial Results
  12. BioPharmX Society of Toxicology Poster Suggests Promise of BPX-01 as Topical Acne Therapy, Highlights Safety
  13. BioPharmX to Present at 29th Annual ROTH Conference
  14. BioPharmX Presents Poster at American Academy of Dermatology Annual Meeting Suggesting BPX-01 Safely, Efficiently Delivers Acne-Fighting Minocycline to Pilosebaceous Units
  15. SPIE Photonics West Presentations to Show BioPharmX was First to Visualize Minocycline on the Skin Using Multiphoton Microscopy
  16. Specialty Pharma Industry Veteran Charles Gregory Vontz Joins BioPharmX Board of Directors
  17. BioPharmX Data Suggest Anti-Inflammatory Activity of BPX-01 Topical Minocycline Gel
  18. BioPharmX Completes Enrollment of BPX-01 Phase 2b OPAL Clinical Trial for Acne Vulgaris
  19. BioPharmX (BPMX) Exited Fiscal Third Quarter with Strong Balance Sheet
  20. BioPharmX Corporation Reports Third Quarter Financial Results